NovoCure Limited
NVCR
$15.58
-$0.25-1.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -168.63M | -149.78M | -168.70M | -192.74M | -207.04M |
| Total Depreciation and Amortization | 9.87M | 9.58M | 9.93M | 9.79M | 9.70M |
| Total Amortization of Deferred Charges | 5.14M | 4.59M | 4.59M | 4.59M | 4.59M |
| Total Other Non-Cash Items | 130.90M | 84.25M | 82.53M | 87.00M | 89.77M |
| Change in Net Operating Assets | -3.65M | 13.90M | 4.49M | 3.19M | 29.66M |
| Cash from Operations | -26.37M | -37.48M | -67.17M | -88.18M | -73.34M |
| Capital Expenditure | -42.86M | -40.73M | -37.30M | -32.79M | -27.09M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -97.39M | 21.20M | 24.84M | 380.87M | 211.24M |
| Cash from Investing | -140.24M | -19.53M | -12.47M | 348.08M | 184.15M |
| Total Debt Issued | 96.92M | 96.92M | 96.92M | -- | -- |
| Total Debt Repaid | -12.91M | -12.91M | -12.91M | -3.00K | -10.00K |
| Issuance of Common Stock | 6.31M | 5.53M | 6.60M | 10.80M | 15.80M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 90.32M | 89.54M | 90.61M | 10.80M | 15.79M |
| Foreign Exchange rate Adjustments | -174.00K | 154.00K | -30.00K | 34.00K | 131.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -76.47M | 32.69M | 10.95M | 270.72M | 126.73M |